# Clinical trials recruiting in Nebraska: 751 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 751 trials recruiting or not yet recruiting with a site in Nebraska, as read on November 19, 2026.

## The full list

Clinical trials recruiting in Nebraska: 751 rows for $37.55, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 13 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/state/nebraska

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 751
- Recruiting or not yet: 751
- Read on: November 19, 2026

## Trials

The 25 newest of 751, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 17, 2026 | NCT07940803 | A Research Study of a New Medicine NNC0662-3168 for Weight Management and Type 2 Diabetes | Novo Nordisk A/S | Phase 1/2 | Not yet recruiting | Overweight, Obesity, Type 2 Diabetes Mellitus | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07940803) |
| November 4, 2026 | NCT07915219 | A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON) | Boehringer Ingelheim | Phase 3 | Not yet recruiting | Bronchiectasis | 1,500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07915219) |
| November 3, 2026 | NCT07914218 | Rural Veteran and Care Partner Walking Program | Creighton University | Not applicable | Recruiting | Mild Cognitive Impairment (MCI) | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07914218) |
| November 3, 2026 | NCT07911852 | Audiological Rehabilitation of Children With Unilateral Hearing Loss | Sponsor not shown (see the record) | Observational | Recruiting | Unilateral Hearing Loss | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07911852) |
| October 29, 2026 | NCT07904026 | Testosterone-Informed De-Escalation in Metastatic Prostate Cancer (TIDE PC) | University of Nebraska | Phase 2 | Not yet recruiting | Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07904026) |
| October 29, 2026 | NCT07903311 | Iron Repletion in Cystic Fibrosis | University of Michigan | Phase 4 | Not yet recruiting | Cystic Fibrosis, Iron Deficiencies, Iron Deficiency Diseases | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07903311) |
| October 27, 2026 | NCT07898072 | Safety and Efficacy of Weekly Testosterone Cypionate Auto-Injector in Men With Hypogonadism | Amneal Pharmaceuticals, LLC | Phase 3 | Recruiting | Male Hypogonadism | 190 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07898072) |
| October 20, 2026 | NCT07882862 | HRT-PC Trial: Hormone Recovery After Treatment for Prostate Cancer Trial. An Open-label Phase II Study of Clomiphene Citrate in Patients... | University of Nebraska | Phase 2 | Not yet recruiting | Prostate Cancer | 83 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07882862) |
| October 14, 2026 | NCT07873931 | A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases | Bristol-Myers Squibb | Phase 1 | Not yet recruiting | Systemic Lupus Erythematosus, Sjögren's Disease, Rheumatoid Arthritis, Idiopathic Inflammatory Myopathies, Systemic... | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07873931) |
| October 9, 2026 | NCT07869381 | Trial Comparing CPDMA Versus Standard Breadloafing in WLE Specimens of Stage 1-II Cutaneous Melanoma | University of Nebraska | Not applicable | Not yet recruiting | Cutaneous Melanoma, Stage II, Cutaneous Melanoma, Acral Melanoma | 282 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07869381) |
| October 9, 2026 | NCT07868926 | Absorption, Distribution, Metabolism, and Excretion of 14C-VX-407 After a Single Oral Dose | Vertex Pharmaceuticals Incorporated | Phase 1 | Recruiting | Autosomal Dominant Polycystic Kidney Disease (ADPKD) | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07868926) |
| October 7, 2026 | NCT07863193 | Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne (AURORA) | Sagimet Biosciences Inc. | Phase 3 | Recruiting | Acne Vulgaris | 800 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07863193) |
| October 7, 2026 | NCT07862582 | RYZ711 Diagnostic Platform Study | RayzeBio, Inc. | Phase 1/2 | Recruiting | Prostate Cancer (Adenocarcinoma), Adenocarcinoma of the Prostate, Metastatic Castration-resistant Prostate Cancer... | 116 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07862582) |
| October 6, 2026 | NCT07861100 | A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular... | Novo Nordisk A/S | Phase 3 | Not yet recruiting | Cardiovascular Risk, Obesity | 8,500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07861100) |
| October 5, 2026 | NCT07859059 | Metronomic Temozolomide With Dexbrompheniramine for Recurrent High-Grade Glioma/Glioblastoma | University of Nebraska | Phase 1/2 | Not yet recruiting | High Grade Glioma, Glioblastoma, Gliosarcoma | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07859059) |
| September 30, 2026 | NCT07850804 | Trial of NASHA Dx Urethral Bulking System | Palette Life Sciences, Inc. | Not applicable | Not yet recruiting | Urinary Incontinence, Urinary Incontinence (UI), Urinary Incontinence , Stress, Urinary Incontinence Due to Urethral... | 314 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07850804) |
| September 29, 2026 | NCT07845786 | Zanzalintinib and Pembrolizumab in First-Line Maintenance for Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) | Exelixis | Phase 2 | Recruiting | Squamous Non-Small Cell Lung Cancer (NSCLC) | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07845786) |
| September 24, 2026 | NCT07839819 | Study of PM54 in Combination With Cytotoxic and Targeted Agents in Adult Participants With Advanced Malignancies | PharmaMar | Phase 1/2 | Not yet recruiting | Advanced Solid Tumor | 231 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07839819) |
| September 21, 2026 | NCT07832071 | Phenolic Dependent And Independent Effects Of Whole Grain Sorghum On Immunometabolism | University of Nebraska Lincoln | Not applicable | Not yet recruiting | Dietary Intervention, Gut Microbiota, Insulin Sensitivity/Resistance, Obesity & Overweight | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07832071) |
| September 18, 2026 | NCT07828613 | Accelerated Flap Coverage Versus Standard Timing in the Treatment of Severe Lower Extremity Musculoskeletal Injuries | Johns Hopkins University | Not applicable | Not yet recruiting | Open Tibia Fracture, Open Dislocation of Ankle, Extremity Fracture Lower, Extremity Injuries Lower | 356 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07828613) |
| September 16, 2026 | NCT07823205 | A Study to Evaluate Different Oral Formulations of KT-621 | Kymera Therapeutics, Inc. | Phase 1 | Recruiting | Healthy Participants | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07823205) |
| September 14, 2026 | NCT07817875 | Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12... | Eli Lilly and Company | Phase 3 | Recruiting | Obesity | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07817875) |
| September 11, 2026 | NCT07816367 | A Study to Assess the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine | TriGemX Bio, Inc. | Phase 3 | Recruiting | Migraine | 1,500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07816367) |
| September 10, 2026 | NCT07813663 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JZP269 in Healthy Male and Female Participants | Jazz Pharmaceuticals | Phase 1 | Recruiting | Healthy Participants | 212 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07813663) |
| September 4, 2026 | NCT07805707 | A Study on the Efficacy of a Vaccine Against Influenza in Adults ≥65 Years of Age | GlaxoSmithKline | Phase 3 | Recruiting | Influenza, Human | 54,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07805707) |

## Sites with the most of these trials

Sites as the records name them, organizations only.

| Site | City | Trials |
| --- | --- | --- |
| University of Nebraska Medical Center | Omaha | 226 |
| Nebraska Medicine-Village Pointe | Omaha | 44 |
| Nebraska Cancer Specialists | Omaha | 41 |
| CHI Health Good Samaritan | Kearney | 41 |
| Nebraska Medicine-Bellevue | Bellevue | 39 |
| Alegent Health Bergan Mercy Medical Center | Omaha | 37 |
| Alegent Health Immanuel Medical Center | Omaha | 35 |
| Alegent Health Lakeside Hospital | Omaha | 35 |
| Nebraska Methodist Hospital | Omaha | 32 |
| Children's Hospital and Medical Center of Omaha | Omaha | 26 |
| Saint Elizabeth Regional Medical Center | Lincoln | 25 |
| Midlands Community Hospital | Papillion | 25 |
| CHI Health Saint Francis | Grand Island | 22 |
| Nebraska Cancer Specialists/Oncology Hematology West PC | Grand Island | 18 |
| Nebraska Cancer Specialists/Oncology Hematology West PC - MECC | Omaha | 17 |
| Cancer Partners of Nebraska | Lincoln | 17 |
| Oncology Associates PC | Omaha | 15 |
| Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE | Omaha | 13 |
| Creighton University Medical Center | Omaha | 13 |
| University Of Nebraska Medical Center | Omaha | 12 |
| Fred and Pamela Buffett Cancer Center - Kearney | Kearney | 11 |
| University of Nebraska | Omaha | 9 |
| Bryan Heart | Lincoln | 9 |
| Boys Town National Research Hospital | Omaha | 8 |
| Oncology Hematology West P.C. dba Nebraska Cancer Specialists | Omaha | 8 |

## By phase

| Phase | Trials |
| --- | --- |
| Early phase 1 | 2 |
| Phase 1 | 50 |
| Phase 1/2 | 45 |
| Phase 2 | 138 |
| Phase 2/3 | 26 |
| Phase 3 | 275 |
| Phase 4 | 20 |
| Not applicable | 111 |
| Observational | 84 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Carcinoma, Non-Small-Cell Lung | 45 |
| Prostatic Neoplasms | 38 |
| Breast Neoplasms | 29 |
| Neoplasms | 25 |
| Colorectal Neoplasms | 22 |
| Heart Failure | 21 |
| Multiple Myeloma | 21 |
| Lung Neoplasms | 21 |
| Neoplasm Metastasis | 19 |
| Ovarian Neoplasms | 19 |
| Melanoma | 17 |
| Squamous Cell Carcinoma of Head and Neck | 17 |
| Diabetes Mellitus, Type 2 | 16 |
| Pancreatic Neoplasms | 16 |
| Lymphoma, Non-Hodgkin | 16 |
| Carcinoma, Renal Cell | 13 |
| Endometrial Neoplasms | 13 |
| Obesity | 12 |
| Lymphoma, Large B-Cell, Diffuse | 11 |
| Recurrence | 11 |
| Urinary Bladder Neoplasms | 11 |
| Carcinoma | 11 |
| Cardiovascular Diseases | 10 |
| Hematologic Neoplasms | 10 |
| Migraine Disorders | 10 |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| University of Nebraska | 60 |
| National Cancer Institute (NCI) | 33 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 30 |
| [Pfizer](https://specstream.ai/data/clinical-trials/company/pfizer) | 26 |
| [Merck Sharp & Dohme LLC](https://specstream.ai/data/clinical-trials/company/merck-sharp-and-dohme-llc) | 20 |
| SWOG Cancer Research Network | 18 |
| Children's Oncology Group | 17 |
| [AbbVie](https://specstream.ai/data/clinical-trials/company/abbvie) | 15 |
| [Bristol-Myers Squibb](https://specstream.ai/data/clinical-trials/company/bristol-myers-squibb) | 15 |
| Alliance for Clinical Trials in Oncology | 15 |
| NRG Oncology | 14 |
| VA Office of Research and Development | 13 |
| [Janssen Research & Development, LLC](https://specstream.ai/data/clinical-trials/company/janssen-research-and-development-llc) | 10 |
| [Novartis Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/novartis-pharmaceuticals) | 9 |
| [GlaxoSmithKline](https://specstream.ai/data/clinical-trials/company/glaxosmithkline) | 9 |
| [Boehringer Ingelheim](https://specstream.ai/data/clinical-trials/company/boehringer-ingelheim) | 8 |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 7 |
| [Hoffmann-La Roche](https://specstream.ai/data/clinical-trials/company/hoffmann-la-roche) | 7 |
| [BeOne Medicines](https://specstream.ai/data/clinical-trials/company/beone-medicines) | 6 |
| [Novo Nordisk A/S](https://specstream.ai/data/clinical-trials/company/novo-nordisk-a-s) | 6 |
| ECOG-ACRIN Cancer Research Group | 6 |
| [Regeneron Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/regeneron-pharmaceuticals) | 5 |
| [Sanofi](https://specstream.ai/data/clinical-trials/company/sanofi) | 5 |
| University of Michigan | 4 |
| [Incyte Corporation](https://specstream.ai/data/clinical-trials/company/incyte-corporation) | 4 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in Nebraska

- [Auto insurance agencies in Nebraska, United States](https://specstream.ai/data/businesses/auto-insurance-agencies/nebraska-united-states)
- [Fence contractors in Nebraska, United States](https://specstream.ai/data/businesses/fence-contractors/nebraska-united-states)
- [Orthodontics practices in Nebraska, United States](https://specstream.ai/data/businesses/orthodontics-practices/nebraska-united-states)
- [American restaurants in Nebraska, United States](https://specstream.ai/data/businesses/american-restaurants/nebraska-united-states)
- [Endodontics practices in Nebraska, United States](https://specstream.ai/data/businesses/endodontics-practices/nebraska-united-states)
- [Music schools in Nebraska, United States](https://specstream.ai/data/businesses/music-schools/nebraska-united-states)
